Drug intelligence / Profile preview

[F-18]MeFAMP

Development stage: Phase 1
Lead developer: University of Alabama at Birmingham
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[F-18]MeFAMP is a radioconjugate composed of the non-natural amino acid (R)-3-fluoro-2-methyl-2-(methylamino)propanoic acid (MeFAMP) radiolabeled with the positron-emitting isotope fluorine-18. It functions as a system A amino acid transport substrate for positron emission tomography (PET) imaging of primary and metastatic brain tumors. The tracer has shown promising results in preclinical models for imaging brain tumors and other malignancies.

Other names: fluorine F 18-labeled MeFAMP3-[18F]fluoro-2-methyl-2-N-(methyl amino) propanoic acid

Targets

SNAT2 (Sodium-coupled neutral amino acid transporter 2)

Beyond the preview

Go deeper on [F-18]MeFAMP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [F-18]MeFAMP.

Explore the full profile